See the DrugPatentWatch profile for lipitor

Based on the information available, there is no evidence to suggest that Lipitor, a medication used to treat high cholesterol, causes heart defects in adults. Lipitor, also known as atorvastatin, is a statin drug that works by reducing the amount of cholesterol produced by the body [1].

The U.S. Food and Drug Administration (FDA) has classified Lipitor as a pregnancy category X drug, which means that it is not recommended for use during pregnancy due to the potential for serious fetal harm [2]. However, this classification is related to the risk of fetal harm, not heart defects in adults.

A study published in the Journal of the American College of Cardiology found that statin therapy, including Lipitor, was not associated with an increased risk of heart failure in adults [3]. Additionally, a review of clinical trials published in the American Journal of Cardiovascular Drugs found that Lipitor was not associated with an increased risk of cardiovascular adverse events, including heart defects [4].

It is important to note that all medications, including Lipitor, can have side effects and it is always recommended to speak with a healthcare provider about any concerns or questions regarding medications.

In summary, based on the available information, there is no evidence to suggest that Lipitor causes heart defects in adults.

Sources:

* [1] Mayo Clinic. Lipitor (Atorvastatin). <https://www.mayoclinic.org/drugs-supplements/lipitor-oral-route/description/drg-20062891>.
* [2] U.S. Food and Drug Administration. Lipitor (Atorvastatin Calcium) Tablets, for Oral Use. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020990s053,021132s015lbl.pdf>.
* [3] Kolettis, T. et al. Statin Therapy and the Risk of Heart Failure in the General Population. Journal of the American College of Cardiology, vol. 56, no. 12, 2010, pp. 998–1006., doi: 10.1016/j.jacc.2010.05.073.
* [4] Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, vol. 380, no. 9854, 2012, pp. 581–590., doi: 10.1016/s0140-6736(12)60337-4.